公开(公告)号：EP3102191A1

公开(公告)日：2016-12-14

申请号：EP15746636.8

申请日：2015-02-05

Applicant: STC.UNM

Inventor： TRUJILLO, Kristina

IPC: A61K9/48 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K35/55 ,  A61K9/0019 ,  A61K31/138 ,  A61K31/337 ,  A61K31/513 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  A61K45/06 ,  A61K2300/00

Abstract: In one embodiment, the invention provides substantially purified exosomes which induce apoptosis in breast cancer cells and which are derived from a cultured medium of histologically normal breast tissue cells that are obtained from tumor-adjacent normal breast tissue. Related methods of treating breast cancer and pharmaceutical formulations are also provided.

公开(公告)号：WO2015120150A1

公开(公告)日：2015-08-13

申请号：PCT/US2015/014623

申请日：2015-02-05

Applicant: STC.UNM

Inventor： TRUJILLO, Kristina

IPC: A61K9/48 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K35/55 ,  A61K9/0019 ,  A61K31/138 ,  A61K31/337 ,  A61K31/513 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  A61K45/06 ,  A61K2300/00

Abstract: In one embodiment, the invention provides substantially purified exosomes which induce apoptosis in breast cancer cells and which are derived from a cultured medium of histologically normal breast tissue cells that are obtained from tumor-adjacent normal breast tissue. Related methods of treating breast cancer and pharmaceutical formulations are also provided.

Abstract translation: 在一个实施方案中，本发明提供了在乳腺癌细胞中诱导细胞凋亡的基本上纯化的外来体，其衍生自从肿瘤相邻的正常乳腺组织获得的组织学上正常的乳腺组织细胞的培养基。 还提供了治疗乳腺癌和药物制剂的相关方法。

公开(公告)号：WO2020112998A1

公开(公告)日：2020-06-04

申请号：PCT/US2019/063602

申请日：2019-11-27

Applicant: STC.UNM ,  K&K BIOTECH ,  TRUJILLO, Kristina ,  UILK, Katie ,  VANDER JAGT, David, L. ,  DECK, Lorraine, M.

Inventor： TRUJILLO, Kristina ,  UILK, Katie ,  VANDER JAGT, David, L. ,  DECK, Lorraine, M.

IPC: A61K31/05 ,  A61K36/28 ,  A61K8/36 ,  A61K8/38 ,  A61K8/67 ,  A61P17/12 ,  A61Q19/00

Abstract: The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFKB and as agonists (activators) ofNrf2. In particular, these compounds show dual activity and it has been discovered that these compounds are particularly useful in the treatment of certain cosmetic applications and in rejuvenating and beautifying skin and other keratinous tissue of a subject in need. Cosmetic compositions and methods of using said compositions in combination with other components are disclosed herein.

公开(公告)号：WO2016081603A1

公开(公告)日：2016-05-26

申请号：PCT/US2015/061349

申请日：2015-11-18

Applicant: STC.UNM

Inventor： TRUJILLO, Kristina ,  GANNON, Nicholas, Patrick ,  VAUGHAN, Roger, Alan

IPC: A61K38/16 ,  A61P35/00

CPC classification number: A61K38/22 ,  A61K31/155 ,  A61K31/337 ,  A61K31/704 ,  A61K38/177 ,  A61K45/06 ,  G01N33/74 ,  G01N2800/7028 ,  A61K2300/00

Abstract: In one embodiment, the invention provides methods of treating or preventing cancer, in particular aspects breast and/or prostate cancer, by administering to a subject in need thereof a therapeutically-effective amount of irisin and, optionally, one or more adjuvant therapies (e.g. synergistic co-administration of an additional anti-cancer agent or chemotherapy). Related pharmaceutical compositions, assays and kits are also provided.

Abstract translation: 在一个实施方案中，本发明提供了治疗或预防癌症，特别是乳腺和/或前列腺癌方面的方法，其通过向有需要的受试者施用治疗有效量的虹啡肽和任选的一种或多种辅助疗法（例如， 协同共同施用另外的抗癌剂或化疗）。 还提供了相关的药物组合物，测定和试剂盒。